Differential impact of inhibitory and activating killer ig-like receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors

Bone Marrow Transplantation

Volumn 47, Issue 6, 2012, Pages 817-823

  Chen, D F ^a   Prasad, V K ^a   Broadwater, G ^a   Reinsmoen, N L ^b   DeOliveira, A ^a   Clark, A ^a   Sullivan, K M ^a   Chute, J P ^a   Horwitz, M E ^a   Gasparetto, C ^a   Long, G D ^a   Yang, Y ^a   Chao, N J ^a   Rizzieri, D A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

activating KIR; haploidentical; hematopoietic SCT; inhibitory KIR; reduced intensity conditioning (RIC)

Indexed keywords

ACTIVATING KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; ALEMTUZUMAB; CYCLOPHOSPHAMIDE; FLUDARABINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; INHIBITORY KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MYCOPHENOLIC ACID; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ARTICLE; BLOOD GROUP INCOMPATIBILITY; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD34 SELECTION; CONTROLLED STUDY; DONOR; GRAFT RECIPIENT; GRAFT VERSUS LYMPHOMA EFFECT; HAPLOIDENTICAL RELATED DONOR; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA MATCHING; HUMAN; LIGAND BINDING; LYMPHOMA; MAJOR CLINICAL STUDY; MORTALITY; MYELOID MALIGNANCY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; RELAPSE RELATED MORTALITY; SURVIVAL TIME; T CELL DEPLETION;

ADOLESCENT; ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TESTING; HLA-C ANTIGENS; HUMANS; LIVING DONORS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECEPTORS, KIR; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84862159242     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.181     Document Type: Article

References (44)

1. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
2. Hale G, Zhang MJ, Bunjes D, Prentice HG, Spence D, Horowitz MM et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graftversus-host disease and graft rejection. Blood 1998; 92: 4581-4590.
3. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865-3871.
4. Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M et al. Partially matched, nonmyeloablative allogeneic transplantation: Clinical outcomes and immune reconstitution. J Clin Oncol 2007; 25: 690-697.
5. Barrett AJ. Understanding and harnessing the graft-versusleukaemia effect. Br J Haematol 2008; 142: 877-888.
6. Trowsdale J. Genetic and functional relationships between MHC and NK receptor genes. Immunity 2001; 15: 363-374.
7. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 1996; 14: 619-648.
8. Lanier LL. NK cell receptors. Annu Rev Immunol 1998; 16: 359-393.
9. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 1999; 17: 875-904.
10. Long EO. Immunology Signal sequences stop killer cells. Nature 1998; 391: 740-743.
11. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9: 503-510.
12. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: Evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009; 113: 3119-3129.
13. Moretta A, Sivori S, Vitale M, Pende D, Morelli L, Augugliaro R et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 1995; 182: 875-884.
14. Stewart CA, Laugier-Anfossi F, Vely F, Saulquin X, Riedmuller J, Tisserant A et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A 2005; 102: 13224-13229.
15. Gratama JW, Sutherland DR, Keeney M. Flow cytometric enumeration and immunophenotyping of hematopoietic stem and progenitor cells. Semin Hematol 2001; 38: 139-147.
16. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213-226.
17. Rizzieri DA, Dev P, Long GD, Gasparetto C, Sullivan KM, Horwitz M et al. Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors. Bone Marrow Transplant 2009; 43: 327-333.
18. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
19. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958; 53: 457-481.
21. Mantel C, Luo Z, Hendrie P, Broxmeyer HE. Steel factor and granulocyte-macrophage colony stimulating factor act together to enhance choline-lipid turnover during synergistically stimulated proliferation of the human factor dependent cell line, M07E. Biochem Biophys Res Commun 1993; 97: 978-984.
22. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102: 814-819.
23. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood 2002; 100: 3825-3827.
24. Brunstein CG, Wagner JE, Weisdorf DJ, Cooley S, Noreen H, Barker JN et al. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood 2009; 113: 5628-5634.
25. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009; 113: 726-732.
26. Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005; 105: 4878-4884.
27. Gagne K, Busson M, Bignon JD, Balere-Appert ML, Loiseau P, Dormoy A et al. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1366-1375.
28. Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: A report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 2006; 12: 876-884.
29. Venstrom JM, Gooley TA, Spellman S, Pring J, Malkki M, Dupont B et al. Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood 2010; 115: 3162-3165.
30. Giebel S, Nowak I, Dziaczkowska J, Czerw T, Wojnar J, Krawczyk-Kulis M et al. Activating killer immunoglobulinlike receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2009; 83: 343-356.
31. Locatelli F, Pende D, Maccario R, Mingari MC, Moretta A, Moretta L. Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: How NK cells make the difference. Clin Immunol 2009; 133: 171-178.
32. Willemze R, Rodrigues CA, Labopin M, Sanz G, Michel G, Socie G et al. KIR-ligand incompatibility in the graftversus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009; 23: 492-500 [Erratum appears in Leukemia. 2009 Mar;23(3):630].
33. Caligiuri MA. Human natural killer cells. Blood 2008; 112: 461-469.
34. Cambiaggi A, Darche S, Guia S, Kourilsky P, Abastado JP, Vivier E. Modulation of T-cell functions in KIR2DL3 (CD158b) transgenic mice. Blood 1999; 94: 2396-2402.
35. Cooley S, McCullar V, Wangen R, Bergemann TL, Spellman S, Weisdorf DJ et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005; 106: 4370-4376.
36. Fehniger TA, Carson WE, Caligiuri MA. Costimulation of human natural killer cells is required for interferon gamma production. Transplant Proc 1999; 31: 1476-1478.
37. Middleton D, Gonzelez F. The extensive polymorphism of KIR genes. Immunology 2010; 129: 8-19.
38. Miller JS. How killers kill. Blood 2008; 112: 213.
39. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: Challenging its predictive value. Blood 2007; 110: 433-440.
40. Shilling HG, McQueen KL, Cheng NW, Shizuru JA, Negrin RS, Parham P. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 2003; 101: 3730-3740.
41. Velardi A, Ruggeri L, Mancusi A, Aversa F, Christiansen FT. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: A tool for immunotherapy of leukemia. Curr Opin Immunol 2009; 21: 525-530.
42. Yu J, Venstrom JM, Liu XR, O'Reilly R, Pring J, Hasan RS et al. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function following T-cell depleted allogeneic hematopoietic cell transplantation. Blood 2009; 113: 3875-3884.
43. Cook MA, Milligan DW, Fegan CD, Darbyshire PJ, Mahendra P, Craddock CF et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLAidentical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 2004; 103: 1521-1526.
44. Bishara A, De SD, Witt CC, Brautbar C, Christiansen FT, Or R et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-Alloreactive T cells causing GVHD. Tissue Antigens 2004; 63: 204-211.